Testicular Cancer

Measurability of Quality Performance Indicators
Version 1.1

To be read in conjunction with:

- Testicular Cancer Clinical Quality Performance Indicators V1.0 (July 2014)
- Testicular QPI Dataset (Latest published version (V1))
Measurability of Quality Performance Indicators for Testicular Cancer

Document control:

This Version

<table>
<thead>
<tr>
<th>Title</th>
<th>Testicular Cancer Measurability of QPIs</th>
<th>Version/Issue Number</th>
<th>1.1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effective From</td>
<td>October 2014</td>
<td>Author</td>
<td>Charlotte Anthony, ISD</td>
</tr>
<tr>
<td>Document Type</td>
<td>Guidance</td>
<td>Document status</td>
<td>Final</td>
</tr>
<tr>
<td>Document Purpose</td>
<td>Final for Publication</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Summary of changes

Revision History

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Status</th>
<th>Summary of Changes</th>
<th>QPI (s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1</td>
<td>Apr 14</td>
<td>Draft</td>
<td>Changes following comments from KMcd</td>
<td>3,8</td>
</tr>
<tr>
<td>0.2</td>
<td>May 14</td>
<td>Draft</td>
<td>For public engagement</td>
<td>All</td>
</tr>
<tr>
<td>0.3</td>
<td>Jun 14</td>
<td>Draft</td>
<td>Changes following public engagement</td>
<td>All</td>
</tr>
<tr>
<td>0.4</td>
<td>Jun 14</td>
<td>Draft</td>
<td>Further changes following public engagement</td>
<td>All</td>
</tr>
<tr>
<td>0.5</td>
<td>Sept 14</td>
<td>Draft</td>
<td>Further changes following public engagement</td>
<td>All</td>
</tr>
<tr>
<td>0.6</td>
<td>Oct 14</td>
<td>Draft</td>
<td>Changes following board review</td>
<td>All</td>
</tr>
<tr>
<td>1.1</td>
<td>July 15</td>
<td>Final</td>
<td>Amendments following 9 month review</td>
<td>1, 6, 7, 9, 10</td>
</tr>
</tbody>
</table>

Updates from Previous Version

<table>
<thead>
<tr>
<th>QPI</th>
<th>Summary of changes (excluding formatting changes) (July 2015)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Denominator added ‘Excluding’</td>
</tr>
<tr>
<td>6</td>
<td>Numerator remove ‘and Final Definitive (or Only) Surgery Performed (Surgery) equal to Orchidectomy – AND [OPCODE1 = N05.2 OR N05.3 OR N06.3 OR N06.6; NR – insert into Denominator; Numerator removed OR[OPCODE = 99] and insert into Not recorded for denominator</td>
</tr>
<tr>
<td>7</td>
<td>Numerator insert ‘within’ 2 weeks and added footnote stating the QPI document will be updated in the future; Denominator remove ‘or Biological Therapy’ – OR 07</td>
</tr>
<tr>
<td>9</td>
<td>Numerator removed [CTDATE AND SURVCTDATE1] AND SURVCTDATE2 &lt;&gt; 10/10/1010] AND [CTDATE AND SURVCTDATE1 AND – Date CT Scan Completed not coded as Not Applicable and Date Surveillance CT Scan 1-2 all not coded as Not Applicable; and Date CT Scan Completed and; Denominator insert 9085/3; NR Numerator removed ‘[CTDATE = 09/09/0909 OR [SURVCTDATE1 OR’</td>
</tr>
<tr>
<td>10</td>
<td>Denominator split into Orchidectomy, Chemotherapy and Radiotherapy</td>
</tr>
</tbody>
</table>
## QPI 1 – Radiological Staging

<table>
<thead>
<tr>
<th>QPI Title:</th>
<th>Patients with testicular cancer should be evaluated with appropriate imaging to detect the extent of disease and guide treatment decision making.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description:</td>
<td>Proportion of patients with testicular cancer who undergo Computed Tomography (CT) scanning, ideally contrast-enhanced CT, of the chest, abdomen and pelvis within 3 weeks of orchidectomy.</td>
</tr>
</tbody>
</table>

**Numerator**
Number of patients with testicular cancer undergoing CT scanning of the chest, abdomen and pelvis within 3 weeks of orchidectomy.

- Date CT Scan Completed minus Date of Surgery less than or equal to 21 days; and Date of CT Scan Completed not coded as Not Applicable.

\[\text{CTDATE} - \text{DSURG} \leq 21 \text{ Days} \text{ AND } \text{CTDATE} <> 10/10/1010\]

**Denominator**
All patients with testicular cancer undergoing orchidectomy (Excluding patients undergoing chemotherapy prior to orchidectomy).

- Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; Surgery Performed (Surgery) (Testicular Cancer) coded as Orchidectomy; and not Date Treatment Started Systemic Anti-Cancer Therapy (SACT) (Testicular Cancer) 1 coded as less than Date of Surgery.

\[\text{OPCODE1} = \text{N05.2 OR N05.3 OR N06.3 OR N06.6} \text{ AND NOT (CHEMDATE1 < DSURG)}\]

**Not recorded for numerator**
Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target.

\[\text{CTDATE} = 09/09/0909 \text{ OR } \text{DSURG} = 09/09/0909\]

**Not recorded for exclusion**
Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard.

\[\text{CHEMDATE1} = 09/09/0909 \text{ OR } \text{DSURG} = 09/09/0909\]

**Not recorded for denominator**
Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard.

\[\text{OPCODE1} = 99\]
<table>
<thead>
<tr>
<th>QPI Title:</th>
<th>Patients with testicular cancer should have pre-operative assessment of the testicle and Serum Tumour Markers (STMs(^a)).</th>
</tr>
</thead>
</table>
| Description: | Proportion of patients with testicular cancer who undergo pre-operative assessment of the testicle which, at a minimum, includes:  
(i) STMs\(^a\), and  
(ii) testicular ultrasound  
Pre-operative Assessment coded as Yes  
\([\text{PREOP} = 01]\) |
| Numerator | Number of patients with testicular cancer undergoing orchidectomy, who undergo a pre-operative assessment of the testicle, which, at a minimum, includes: (i) STMs (ii) testicular ultrasound.  
Pre-operative Assessment coded as Yes  
\([\text{PREOP} = 01]\) |
| Denominator | All patients with testicular cancer undergoing orchidectomy.  
(Excluding patients who refuse to undergo assessment and Patients undergoing chemotherapy prior to orchidectomy).  
Date of Diagnosis [\text{DIAGDATE}] in range specified for comparative analysis; Final Definitive (or Only) Surgery Performed (Surgery) (Testicular Cancer) coded as Primary Orchidectomy; and Pre-operative Assessment not coded as Patient Refused.  
\([\text{OPCODE1} = \text{N05.2 OR N05.3 OR N06.3 OR N06.6 AND [PREOP <> 95]} \text{ AND NOT ([CHEMDATE1 < DSURG])}]\) |
| Not recorded for numerator | Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target  
\([\text{PREOP} = 99]\) |
| Not recorded for exclusion | Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard.  
\([\text{PREOP} = 99] \text{ OR [CHEMDATE1 = 09/09/0909]} \text{ OR [DSURG = 09/09/0909]}\) |
| Not recorded for denominator | Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard  
\([\text{OPCODE1} = 99]\) |

\(^a\) AFP – Alpha Feta Protein,  
HCG – Human chorionic Gonadotrophin  
LDH – Lactate dehydrogenase
### QPI 3 – Primary orchidectomy

<table>
<thead>
<tr>
<th><strong>QPI Title:</strong></th>
<th>Patients with testicular cancer should have primary orchidectomy within 2 weeks of ultrasonographic diagnosis.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Description:</strong></td>
<td>Proportion of patients with testicular cancer who undergo primary orchidectomy within 2 weeks of ultrasonographic diagnosis.</td>
</tr>
</tbody>
</table>
| **Numerator** | Number of patients with testicular cancer undergoing primary orchidectomy who undergo primary orchidectomy within 2 weeks of ultrasonographic diagnosis.  
Date of Surgery minus Date of Ultrasound Diagnosis (Testicular Cancer) less than or equal to 14 days.  
[DSURG – DUSS <= 14 days] |
| **Denominator** | All patients with testicular cancer undergoing orchidectomy.  
(Excluding patients undergoing chemotherapy prior to orchidectomy).  
Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; and Final Definitive (or Only) Surgery Performed (Surgery) (Testicular Cancer) coded as Primary Orchidectomy; and not Date Treatment Started Systemic Anti-Cancer Therapy (SACT) (Testicular Cancer) 1 coded as less than Date of Surgery.  
[OPCODE1 = N05.2 OR N05.3 OR N06.3 OR N06.6] AND NOT ( [CHEMDATE1 < DSURG]) |

**Not recorded for numerator**  
Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target  
[DSURG = 09/09/0909] OR [DUSS = 09/09/0909]

**Not recorded for exclusion**  
Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard.  
[CHEMDATE1 = 09/09/0909] OR [DSURG = 09/09/0909]

**Not recorded for denominator**  
Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard  
[OPCODE1 = 99]
| **QPI Title:** | Patients with testicular cancer should be discussed by a Multi Disciplinary Team (MDT) to agree a definitive management plan post orchidectomy with staging and pathology. |
| **Description:** | Proportion of patients with testicular cancer who are discussed at an MDT meeting to agree a definitive management plan post orchidectomy. |
| **Numerator** | Number of patients with testicular cancer undergoing orchidectomy who are discussed at the MDT to agree a definitive management plan post orchidectomy. |
| | Date Discussed by Care Team (MDT) not coded as Not Applicable; and Date Discussed by Care Team (MDT) coded as following Date of Surgery. |
| | [MDTDATE <> 10/10/1010] AND [MDTDATE > DSURG] |
| **Denominator** | All patients with testicular cancer undergoing orchidectomy. (No exclusions). |
| | Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; and Final Definitive (or Only) Surgery Performed (Surgery) (Testicular Cancer) coded as Primary Orchidectomy; |
| | [OPCODE1 = N05.2 OR N05.3 OR N06.3 OR N06.6] |
| **Not recorded for numerator** | Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target |
| | [MDTDATE = 09/09/0909] OR [DSURG = 09/09/0909] |
| **Not recorded for exclusion** | Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard. |
| **Not recorded for denominator** | Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard |
| | [OPCODE1 = 99] |
### QPI 5 – Pathology Reporting

<table>
<thead>
<tr>
<th>QPI Title:</th>
<th>All pathology reports for testicular cancer should contain full pathology information to inform patient management.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description:</td>
<td>Proportion of patients with testicular cancer undergoing orchidectomy where the pathology report contains tumour type and size, vascular invasion and rete stromal invasion (based upon the current Royal College of Pathologists dataset).</td>
</tr>
</tbody>
</table>

**Numerator**

Number of patients with testicular cancer undergoing primary orchidectomy where histological pathology report contains tumour type and size, vascular invasion and rete stromal invasion (based upon the current Royal College of Pathologists dataset).

Morphology of Tumour (Testicular Cancer) not coded as Not Recorded; and Tumour Size not coded as Not Recorded; and Vascular Invasion not coded as Not Recorded; and Rete Stromal Invasion not coded as Not Recorded

\[
\text{MORPHOL} \neq 9999/9 \ \text{AND} \ \text{TSIZE} \neq 9999 \ \text{AND} \ \text{VASCINV} \neq 99 \ \text{AND} \ \text{RSINV} \neq 99
\]

**Denominator**

All patients with testicular cancer undergoing orchidectomy. (No exclusions).

Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; and Final Definitive (or Only) Surgery Performed (Surgery) (Testicular Cancer) coded as Primary Orchidectomy.

\[
\text{OPCODE1} = \text{N05.2 OR N05.3 OR N06.3 OR N06.6}
\]

**Not recorded for numerator**

Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target.

*Patients not recorded for MORPHOL, TSIZE, VASCINV and RSINV are included in the numerator not met category for this QPI.*

**Not recorded for exclusion**

Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard.

**Not recorded for denominator**

Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard.

\[
\text{OPCODE1} = 99
\]
### QPI 6 – Adjuvant treatment of stage I seminoma with carboplatin

<table>
<thead>
<tr>
<th><strong>QPI Title:</strong></th>
<th>Patients with stage I seminoma receiving adjuvant single dose carboplatin should have an AUC of 7mg/ml/min based on ethylene diamine tetra-acetic acid (EDTA) clearance.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Description:</strong></td>
<td>Proportion of patients with stage I seminoma receiving adjuvant single dose carboplatin who have an AUC of 7mg/ml/min based on EDTA clearance within 8 weeks of orchidectomy.</td>
</tr>
</tbody>
</table>
| **Numerator** | Number of patients with stage I seminoma undergoing adjuvant single dose carboplatin AUC 7, based on EDTA clearance, within 8 weeks of orchidectomy.  
Date Treatment Started Systemic Anti-Cancer Therapy (SACT) (Testicular Cancer) minus Date of Surgery less than or equal to 56 days; and Calculation of Renal Function coded as EDTA.  
\[CHEMDATE1 - DSURG <= 56 \text{ days}] \text{ AND } [CALC=01] |
| **Denominator** | All patients with stage I seminoma undergoing adjuvant single dose carboplatin AUC 7 (Excluding patients who are treated within a clinical trial).  
Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; Stage Grouping (Testicular Cancer) coded as Stage 1; and Morphology of Tumour coded as Seminoma; and Type of Systemic Anti Cancer Therapy (SACT) coded as Adjuvant Single Agent Therapy; and Final Definitive (or Only) Surgery Performed (Surgery) equal to Orchidectomy; and Patient entered into Clinical Trial not coded as Yes – Chemotherapy Trial or Yes – Other Trial.  
\[[\text{STAGE} = \text{I OR IA OR IB}] \text{ AND } [\text{MORPHOL} = \text{9061/3 OR 9063/3}] \text{ AND } [\text{CHEMTYPE1} = \text{08}] \text{ AND } [\text{OPCODE1} = \text{N05.2 OR N05.3 OR N06.3 OR N06.6}] \text{ AND } [\text{TRIAL} <> \text{01A OR 01B}]] |
| **Not recorded for numerator** | Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target  
\[[\text{CHEMDATE1} = \text{09/09/0909}] \text{ OR } [\text{DSURG} = \text{09/09/0909}] \text{ OR } [\text{CALC} = \text{99}]] |
| **Not recorded for exclusion** | Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard  
\[[\text{TRIAL} = \text{99}]] |
| **Not recorded for denominator** | Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard  
\[[\text{STAGE} = \text{99}] \text{ OR } [\text{MORPHOL} = \text{9999/9}] \text{ OR } [\text{CHEMTYPE1} = \text{99}] \text{ OR } [\text{OPCODE1} = \text{99}]] |
**QPI 7 – Serum Tumour Markers**

<table>
<thead>
<tr>
<th><strong>QPI Title:</strong></th>
<th>Patients with metastatic testicular cancer should undergo Serum Tumour Markers (STMs)* before starting chemotherapy to determine their correct International Germ Cell Cancer Collaborative Group (IGCCCG) prognostic grouping.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Description:</strong></td>
<td>Proportion of patients with metastatic testicular cancer who undergo STMs* 2 weeks before starting chemotherapy.</td>
</tr>
</tbody>
</table>
| **Numerator**   | Number of patients with metastatic testicular cancer undergoing chemotherapy who have STMs* checked within 2 weeks before starting chemotherapy.  
                      Date of Serum Tumour Markers Test (Pre-SACT) not coded as Not Applicable; Date Treatment Started Systemic Anti-Cancer Therapy (SACT) (Testicular Cancer) minus Date of Serum Tumour Markers Test (Pre-SACT) less than or equal to 14 days; and Date Treatment Started Systemic Anti-Cancer Therapy (SACT) (Testicular Cancer) not coded as Not Applicable.  
                      \[\text{STMDATE} <> 10/10/1010 \text{ AND} [\text{CHEMDATE1} – \text{STMDATE} <= 14 \text{ days}] \text{ AND} [\text{CHEMDATE1} <> 10/10/1010]\] |
| **Denominator** | All patients with metastatic testicular cancer undergoing chemotherapy *(No exclusions).*  
                      Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; and Stage Grouping (Testicular Cancer) coded as metastatic; and Type of Systemic Anti-Cancer Therapy (SACT) (Testicular Cancer) coded as Neoadjuvant or Adjuvant or Palliative or Chemoradiotherapy or Adjuvant Single Agent Therapy.  
                      \[\text{STAGE} = \text{IS OR II OR IIA OR IIB OR IIC OR III OR IIIA OR IIIB OR IIIC} \text{ AND} [\text{CHEMTYPE1} = 01 \text{ OR} 02 \text{ OR} 04 \text{ OR} 05 \text{ OR} 08]\] |
| Not recorded for numerator | Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target  
                      \[\text{STMDATE} = 09/09/0909 \text{ OR} [\text{CHEMDATE1} = 09/09/0909]\] |
| Not recorded for exclusion | Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard.  
                      \[\text{STAGE} = 99 \text{ OR} [\text{CHEMTYPE1} = 99]\] |
| Not recorded for denominator | Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard.  
                      \[\text{STAGE} = 99 \text{ OR} [\text{CHEMTYPE1} = 99]\] |

---

* Clinical Performance Indicators V1.0 will be updated in the future to reflect change.
### QPI 8 – Systemic Therapy

**QPI Title:** Patients with metastatic testicular cancer who are undergoing systemic therapy should receive Systemic Anti-Cancer Therapy (SACT) within 3 weeks of a MDT decision to treat with SACT.

**Description:** Proportion of patients with metastatic testicular cancer who undergo SACT within 3 weeks of a MDT decision to treat with SACT.

**Numerator**

Number of patients with metastatic testicular cancer undergoing SACT within 3 weeks of an MDT decision to treat with SACT.

- Date SACT Discussed by Care Team (MDT) not coded as Not Applicable; and Date Treatment Started Systemic Anti-Cancer Therapy (SACT) (Testicular Cancer) minus Date SACT Discussed by Care Team (MDT) coded as less than or equal to 3 weeks; and Date Treatment Started Systemic Anti-Cancer Therapy (SACT) (Testicular Cancer) not coded as Not Applicable.

\[
[SMDTDATE \neq 10/10/1010] \text{ AND } [CHEMDATE1 - SMDTDATE \leq 3 \text{ weeks}] \text{ AND } [CHEMDATE1 \neq 10/10/1010]
\]

**Denominator**

All patients with metastatic testicular cancer undergoing SACT (Excluding patients whose primary chemotherapy management is as part of a chemotherapy clinical trial).

- Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; and Stage Grouping (Testicular Cancer) coded as metastatic; and Type of Systemic Anti-Cancer Therapy (SACT) (Testicular Cancer) coded as Neoadjuvant or Adjuvant or Palliative or Chemoradiotherapy or Biological Therapy or Adjuvant Single Agent Therapy; and Patient entered into Clinical Trial not coded as Yes – Chemotherapy Trial.

\[
[STAGE = IS \text{ OR } II \text{ OR } IIA \text{ OR } IIB \text{ OR } III \text{ OR } IIIA \text{ OR } IIIB \text{ OR } IIIC] \text{ AND } [CHEMTYPE1 = 01 \text{ OR } 02 \text{ OR } 04 \text{ OR } 05 \text{ OR } 07 \text{ OR } 08] \text{ AND } [TRIAL \neq 01]
\]

**Not recorded for numerator**

Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target

\[
[SMDTDATE = 09/09/0909] \text{ OR } [CHEMDATE1 = 09/09/0909]
\]

**Not recorded for exclusion**

Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard.

\[
[TRIAL = 99]
\]

**Not recorded for denominator**

Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard

\[
[STAGE = 99] \text{ OR } [CHEMTYPE1 = 99]
\]

*Please note:* patients taking part in trials that are not related to chemotherapy should be included.
QPI 9 – Computed Tomography scanning for surveillance patients

<table>
<thead>
<tr>
<th>QPI Title:</th>
<th>Patients with stage I testicular non-seminomatous (or mixed) germ cell tumour (NSGCT) under surveillance should undergo Computed Tomography (CT) scanning of the abdomen +/- chest and pelvis as per clinical relevance.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description:</td>
<td>Proportion of patients with stage I testicular NSGCT (or mixed) under surveillance who undergo at least three CT scans of the abdomen +/- chest and pelvis within 14 months of diagnosis.</td>
</tr>
</tbody>
</table>
| Numerator | Patients with stage I testicular non-seminomatous (or mixed) germ cell tumour who undergo at least three CT scans of the abdomen +/- chest and pelvis within 14 months of diagnosis.  
Date Surveillance CT Scan 1-2 minus Date of Diagnosis less than or equal to 14 months.  
[SURVCTDATE2 – DIAGDATE <= 14 months] |
| Denominator | All patients with stage I testicular non-seminomatous (or mixed) germ cell tumour. *(Excluding patients who have received adjuvant chemotherapy and patients who are treated within a clinical trial).*  
Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; and Stage Grouping coded as I; and Morphology of Tumour coded as Mixed Germ Cell; and Type of Systemic Anti-Cancer Therapy (SACT) 1-3 not coded as Adjuvant; AND Patient entered into Clinical Trial not coded as Yes – Chemotherapy Trial or Yes – Other Trial.  
[STAGE = I OR IA OR IB] AND [MORPHOL = 9100/3 OR 9065/3 OR 9070/3 OR 9080/3 OR 9071/3 OR 9081/3 OR 9085/3] AND [CHEMTYPE1 OR CHEMTYPE2 OR CHEMTYPE3 <> 02 OR 08] AND [TRIAL <> 01A OR 01B] |
| Not recorded for numerator | Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target  
[SURVCTDATE2 = 09/09/0909] OR [DIAGDATE = 09/09/0909] |
| Not recorded for exclusion | Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard.  
[CHEMTYPE1 OR CHEMTYPE2 OR CHEMTYPE3 = 99] OR [TRIAL = 99] |
| Not recorded for denominator | Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard  
[STAGE = 99] OR [MORPHOL = 9999/9] |
### QPI Title:
30 day mortality following treatment for testicular cancer.

### Description:
Proportion of patients with testicular cancer who die within 30 days of treatment for testicular cancer.

### Numerator
Number of patients with testicular cancer who receive treatment who die within 30 days of treatment.

(i) **Orchidectomy**
Date of Death not coded as Not Applicable; and Date of Death minus Date of Surgery less than or equal to 30 days.

[DOD <> 10/10/1010] AND [DOD – DSURG <= 30 DAYS]

(ii) **Chemotherapy**
Date of Death not coded as Not Applicable; and Date of Death minus Date Treatment Completed Systemic Anti-Cancer Therapy (SACT) (Testicular Cancer) 1-3 less than or equal to 30 days.

[DOD <> 10/10/1010] AND ((CHEMTYPE1 = 01 OR 02 OR 04 OR 05 OR 08] AND [DOD - CHEMENDATE1 ≤ 30 DAYS]) OR ([CHEMTYPE2 = 01 OR 02 OR 04 OR 05 OR 08] AND [DOD - CHEMENDATE2 ≤ 30 DAYS]) OR ([CHEMTYPE3 = 01 OR 02 OR 04 OR 05 OR 08] AND [DOD - CHEMENDATE3 ≤ 30 DAYS])

(iii) **Radiotherapy**
Date of Death not coded as Not Applicable; and Date of Death minus Date Treatment Completed (Testicular Cancer) (Radiotherapy) less than or equal to 30 days.

[DOD <> 10/10/1010] AND ([DOD – RCOMPDATE <= 30 DAYS])

### Denominator
All patients with testicular cancer.

(i) **Orchidectomy**
Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; Surgery Performed (Surgery) (Testicular Cancer) coded as Orchidectomy.

[OPCODE1 = N05.2 OR N05.3 OR N06.3 OR N06.6]

(ii) **Chemotherapy**
Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; Type of Systemic Anti-Cancer Therapy equal to Neoadjuvant or Adjuvant or Palliative or Chemoradiotherapy or Adjuvant Single Agent Therapy – Carboplatin AUC 7
Radiotherapy

Date of Diagnosis [DIAGDATE] in range specified for comparative analysis; Radiotherapy equal to Adjuvant or Radical or Palliative or Neo-adjuvant or Chemoradiotherapy.

[RADIO = 01 OR 03 OR 04 OR 05 OR 06]

<table>
<thead>
<tr>
<th>Not recorded for numerator</th>
<th>Include in the denominator for measurement against the target. Present as not recorded only if the patient cannot otherwise be identified as having met/not met the target</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i)</td>
<td>[DOD = 09/09/0909] OR [DSURG = 09/09/0909]</td>
</tr>
<tr>
<td>(ii)</td>
<td>[DOD = 09/09/0909] OR [CHEMENDDATE1 OR CHEMENDDATE2 OR CHEMENDDATE3 = 09/09/0909]</td>
</tr>
<tr>
<td>(iii)</td>
<td>[DOD = 09/09/0909] OR [RCOMPDATE = 09/09/0909]</td>
</tr>
</tbody>
</table>

| Not recorded for exclusion | Include in the denominator for measurement against the target unless there is other definitive evidence that the record should be excluded. Present as not recorded only where the record cannot otherwise be definitively identified as an inclusion/exclusion for this standard |

<table>
<thead>
<tr>
<th>Not recorded for denominator</th>
<th>Exclude from the denominator for measurement against the target. Present as not recorded only where the patient cannot otherwise be definitively identified as an inclusion/exclusion for this standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i)</td>
<td>[OPCODE1 = 99]</td>
</tr>
<tr>
<td>(ii)</td>
<td>[CHEMTYPE1 OR CHEMTYPE2 OR CHEMTYPE3 = 99]</td>
</tr>
<tr>
<td>(iii)</td>
<td>[RADIO =99]</td>
</tr>
</tbody>
</table>